C
46.67
-0.75 (-1.58%)
| Penutupan Terdahulu | 47.42 |
| Buka | 47.52 |
| Jumlah Dagangan | 557,881 |
| Purata Dagangan (3B) | 1,607,912 |
| Modal Pasaran | 4,428,601,856 |
| Harga / Jualan (P/S) | 2.77 |
| Harga / Buku (P/B) | 4.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Operasi (TTM) | -30,860.11% |
| EPS Cair (TTM) | -3.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -43.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.05% |
| Nisbah Semasa (MRQ) | 22.53 |
| Aliran Tunai Operasi (OCF TTM) | -261.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -155.77 M |
| Pulangan Atas Aset (ROA TTM) | -20.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Crinetics Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.8
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.75 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.03% |
| % Dimiliki oleh Institusi | 112.39% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 143.00 (JMP Securities, 206.41%) | Beli |
| Median | 82.00 (75.70%) | |
| Rendah | 40.00 (Goldman Sachs, -14.29%) | Pegang |
| Purata | 82.13 (75.98%) | |
| Jumlah | 7 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 42.70 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citizens | 07 Nov 2025 | 108.00 (131.41%) | Beli | 40.00 |
| Oppenheimer | 30 Sep 2025 | 87.00 (86.42%) | Beli | 41.65 |
| Leerink Partners | 29 Sep 2025 | 88.00 (88.56%) | Beli | 43.51 |
| Morgan Stanley | 29 Sep 2025 | 77.00 (64.99%) | Beli | 43.51 |
| Baird | 26 Sep 2025 | 62.00 (32.85%) | Beli | 45.91 |
| Goldman Sachs | 26 Sep 2025 | 40.00 (-14.29%) | Pegang | 45.91 |
| JMP Securities | 26 Sep 2025 | 143.00 (206.41%) | Beli | 45.91 |
| JP Morgan | 24 Sep 2025 | 52.00 (11.42%) | Beli | 35.18 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |